C4 Therapeutics (CCCC) Financials

C4 Therapeutics’ second-quarter 2026 results show modest revenue improvement and a narrower operating loss, but the company remains unprofitable and dependent on its substantial investment portfolio to fund operations.

Revenue increased to $6.6 million in Q2 2026 from $6.2 million in Q1 2026 and $6.5 million in Q2 2025. However, revenue remains well below the $12.0 million reported in Q2 2024 and the $15.4 million recorded in Q3 2024. With no reported cost of revenue, gross profit matched revenue, but operating expenses totaled $33.1 million, including $24.5 million of research and development spending.

The net loss improved to $23.6 million, or $0.18 per diluted share, compared with a $25.1 million loss in Q1 2026 and a $26.0 million loss in Q2 2025. The improvement was helped by lower selling, general and administrative expenses and higher interest and investment income. Nevertheless, C4 Therapeutics continues to post sizable operating losses, and accumulated retained earnings were negative $787.5 million at the end of Q2.

Liquidity remains the company’s strongest financial feature. Cash and short-term investments totaled approximately $251.2 million at June 30, 2026, up from $236.0 million at the end of Q1 and $214.3 million a year earlier. Including long-term investments, total cash and investments approached $298 million. The balance sheet also shows no traditional short-term or long-term debt balances, although total liabilities were $112.1 million.

• Revenue edged higher: Q2 revenue increased approximately 8% sequentially to $6.6 million and was modestly above Q2 2025.
• Operating losses narrowed: The operating loss improved to $26.4 million in Q2 2026 from $27.8 million in Q1 and $28.5 million in Q2 2025. The figure also benefited from the absence of the $10.7 million impairment charge reported in Q3 2025.
• Liquidity strengthened: Cash and short-term investments increased to $251.2 million from $214.3 million one year earlier, while total cash and investments, including long-term holdings, were approximately $298 million.
• Limited traditional debt: The balance sheet does not report short-term or long-term debt, reducing interest-rate and refinancing pressure.
• Lower corporate overhead: Selling, general and administrative expense fell to $8.6 million in Q2 2026 from $9.3 million in Q1 and $9.2 million in Q4 2025.
• Deferred revenue increased: Current and noncurrent deferred revenue totaled approximately $40.4 million, compared with $31.8 million in Q2 2025, indicating a larger balance of revenue that may be recognized in future periods.
• Cash flow was highly volatile: Operating cash flow improved from negative $29.9 million in Q1 2026 to negative $1.6 million in Q2, largely because changes in operating assets and liabilities provided $17.5 million. This improvement may not be recurring.
• Investment income remains important: Interest and investment income contributed $2.8 million in Q2 2026, helping reduce the net loss but not replacing operating revenue.
• The company remains structurally unprofitable: C4 Therapeutics has reported substantial net losses in each of the periods provided, with Q2 2026’s $23.6 million loss still exceeding the $17.7 million loss reported in Q2 2024.
• Share dilution is a significant risk: Weighted-average diluted shares increased to 130.7 million in Q2 2026 from 126.1 million in Q1 and 82.9 million in Q4 2025. The company also raised $118.7 million through common-stock issuance in Q4 2025.

Overall, C4 Therapeutics has a well-capitalized balance sheet and appears to have meaningful financial flexibility, but its investment case still depends on improving revenue from its pipeline and reducing its recurring cash burn. Investors should monitor whether the recent improvement in operating cash flow persists, as well as the company’s ongoing research spending and potential need for additional equity financing.